HeartBeam, Inc.·Healthcare

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time.

HeartBeam, Inc. (NASDAQ: BEAT - Get Free Report) Director Mark Strome acquired 750,000 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was bought at an average price of $0.80 per share, with a total value of $600,000.00. Following the acquisition, the director directly owned 3,650,000 shares in the company, valued

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of $10 Million Public Offering of Common Stock.
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Healthcare
Medical - Healthcare Information Services
21
2021-11-11
-0.87